812 related articles for article (PubMed ID: 25929338)
1. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
Jia X; Cheng J; Shen Z; Shao Z; Liu G
Mol Med Rep; 2018 Apr; 17(4):5470-5476. PubMed ID: 29393454
[TBL] [Abstract][Full Text] [Related]
3. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
[TBL] [Abstract][Full Text] [Related]
4. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
5. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Fox EM; Miller TW; Balko JM; Kuba MG; Sánchez V; Smith RA; Liu S; González-Angulo AM; Mills GB; Ye F; Shyr Y; Manning HC; Buck E; Arteaga CL
Cancer Res; 2011 Nov; 71(21):6773-84. PubMed ID: 21908557
[TBL] [Abstract][Full Text] [Related]
6. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
7. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Sabnis G; Brodie A
Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
[TBL] [Abstract][Full Text] [Related]
8. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
Generali D; Buffa FM; Berruti A; Brizzi MP; Campo L; Bonardi S; Bersiga A; Allevi G; Milani M; Aguggini S; Papotti M; Dogliotti L; Bottini A; Harris AL; Fox SB
J Clin Oncol; 2009 Jan; 27(2):227-34. PubMed ID: 19064988
[TBL] [Abstract][Full Text] [Related]
10. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
[TBL] [Abstract][Full Text] [Related]
11. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
12. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer.
Sugie T; Suzuki E; Yamauchi A; Yamagami K; Masuda N; Gondo N; Sumi E; Ikeda T; Tada H; Uozumi R; Kanao S; Tanaka Y; Hamazaki Y; Minato N; Toi M
Breast; 2018 Apr; 38():114-119. PubMed ID: 29310035
[TBL] [Abstract][Full Text] [Related]
14. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
Cheng J; Lei L; Xu J; Sun Y; Zhang Y; Wang X; Pan L; Shao Z; Zhang Y; Liu G
J Nucl Med; 2013 Mar; 54(3):333-40. PubMed ID: 23401605
[TBL] [Abstract][Full Text] [Related]
15. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.
Rhodes LV; Short SP; Neel NF; Salvo VA; Zhu Y; Elliott S; Wei Y; Yu D; Sun M; Muir SE; Fonseca JP; Bratton MR; Segar C; Tilghman SL; Sobolik-Delmaire T; Horton LW; Zaja-Milatovic S; Collins-Burow BM; Wadsworth S; Beckman BS; Wood CE; Fuqua SA; Nephew KP; Dent P; Worthylake RA; Curiel TJ; Hung MC; Richmond A; Burow ME
Cancer Res; 2011 Jan; 71(2):603-13. PubMed ID: 21123450
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
17. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
18. Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.
Kopecka J; Porto S; Lusa S; Gazzano E; Salzano G; Giordano A; Desiderio V; Ghigo D; Caraglia M; De Rosa G; Riganti C
Oncotarget; 2015 Oct; 6(31):31461-78. PubMed ID: 26372812
[TBL] [Abstract][Full Text] [Related]
19. Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.
Li G; Shan C; Liu L; Zhou T; Zhou J; Hu X; Chen Y; Cui H; Gao N
PLoS One; 2015; 10(2):e0117440. PubMed ID: 25659153
[TBL] [Abstract][Full Text] [Related]
20. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]